Magrolimab data in MDS, AML raise bar for anti-CD47s, lift Forty Seven shares

With Phase Ib data that appear to be stronger than any previously reported clinical data for anti-CD47 mAbs, Forty Seven became one of the clear winners at the American Society of Hematology meeting, adding over $630 million in value Monday and bringing its market cap to about $1.3 billion (see “Eat This, Don’t Eat That: CD47 Companies’ First Hurdle”).

Forty Seven Inc. (NASDAQ:FTSV) rose $15.99 (111%) to $30.43 after reporting updated data at ASH that showed robust durability in addition to high response rates for magrolimab in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). The company also provided a clearer picture of its regulatory strategy for the anti-CD47 mAb in MDS...